The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Equity issuance costs | 0 |
| Shares issued to ceo for achieving of ip agreement milestones | 0 |
| Loss on settlement of liabilities | 0 |
| Loss on equity issuance | 0 |
| Discount amortization and interest expenses related to promissory notes | 0 |
| Linkage difference on principal of loans from stockholders | 0 |
| Net loss | -19,388 |
| Depreciation | 42 |
| Loss on fixed asset disposal | -16 |
| Issuance of restricted shares as compensation to directors | 122 |
| Amortization of original issue discount related to promissory note | 182 |
| Change in fair value of derivative liability | -3,267 |
| Decrease (increase) in other current assets | 133 |
| Increase in accounts payable | 325 |
| Increase (decrease) in other current liabilities | 17 |
| Loss on series a warrant repurchase | 99 |
| Stock-based compensation | 211 |
| Net cash used in operating activities | -15,240 |
| Purchase of property and equipment | 96 |
| Net cash used in investment activities | -96 |
| Issuance of promissory notes and detachable warrants through private placement transaction | 0 |
| Issuance of convertible promissory notes - related parties | 0 |
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction | 0 |
| Proceeds Received From Underwritten Public Offering | 0 |
| Net | 10,665 |
| Net proceeds from december 2025 private placement transaction | 3,544 |
| Proceeds from promissory note, net of original issue discount of 600 | 3,000 |
| Series a warrant repurchase | 166 |
| Net cash provided by financing activities | 17,043 |
| Effect of exchange rate changes on cash and cash equivalents | 49 |
| Change in cash, cash equivalents, and restricted cash | 1,756 |
| Cash, cash equivalents, and restricted cash at beginning of the year | 5,627 |
| Cash, cash equivalents, and restricted cash at end of the year | 7,383 |
Glucotrack, Inc. (GCTK)
Glucotrack, Inc. (GCTK)